Dymista suksesshistorie

Dymista^®

Dymista^® er en vellykket behandling som er basert på følgende

De gode resultatene Dymista^® viser i kliniske studier^1-3 og i "real life" studier^4-16, er basert på den avanserte formuleringen¹⁸ og sprayflasken¹⁸, i tillegg til de komplementære virkningsmåtene til FP og AZE¹⁷.

De komplementære virkningsmåtene til flutikason (FP) og azelastin (AZE)¹⁷
Formuleringen¹⁸
Sprayflasken¹⁸

Formulering bidrar til effekten

Formuleringen i Dymista^® kan ha bidratt til den gode behandlingseffekten som ble

observert i studier, sammenlignet med kommersielt tilgjengelige konkurrenter.

Høyere biotilgjengelighet av FP¹⁸
Dymista^® er en tiksotrop væske. Mer eller mindre tyntflytende, dette er en fordel ved bruk¹⁹

Dymista^®'s formulering er isoton, osmotisk og har en justert pH tilpasset nesefysiologien¹⁹
Dymista^® inneholder glyserol, og det bidrar til å holde neseslimhinnen fuktig¹⁹
Bedre effekt sammenlignet med monoterapi^{1, 2}

Sprayflasken²⁰ bidrar til effekten.

Biofarmasøytiske egenskaper som bidrar til de kliniske fordelene:

AZE: azelastin; FP: flutikasonpropionat

Referanser:

Carr W, Bernstein J, Lieberman P, et al. A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis. J Allergy Clin Immunol. 2012;129(5):1282-1289.e10.
Meltzer E, Ratner P, Bachert C, et al. Clinically relevant effect of a new intranasal therapy (MP29-02) in allergic rhinitis assessed by responder analysis. Int Arch Allergy Immunol. 2013;161(4):369-377.
Price D, Shah S, Bhatia S, et al. A new therapy (MP29-02) is effective for the long-term treatment of chronic rhinitis. J Investig Allergol Clin Immunol. 2013;23(7):495-503.
Klimek L, Bachert C, Mösges R, et al. Effectiveness of MP29-02 for the treatment of allergic rhinitis in real-life: results from a noninterventional study. Allergy Asthma Proc. 2015;36(1):40-47.
Klimek L, Bachert C, Stjärne P, et al. MP-AzeFlu provides rapid and effective allergic rhinitis control in real life: A pan-European study. Allergy Asthma Proc. 2016;37(5):376-386.
Scadding G, Price D, El-Shanawany T, et al. Multicentre, non-interventional study to assess the profile of patients with uncontrolled rhinitis prescribed a novel formulation of azelastine hydrochloride and fluticasone propionate in a single spray in routine clinical practice in the UK. BMJ Open. 2017;7(4):e014777.
Agache I, Doros IC, Leru PM, Bucur I, Poenaru M, Sarafoleanu C. MP-AzeFlu provides rapid and effective allergic rhinitis control: results of a non-interventional study in Romania. Rhinology. 2018;56(1):33-41.
Haahr PA, Jacobsen C, Christensen ME. MP-AzeFlu provides rapid and effective allergic rhinitis control: results of a non-interventional study in Denmark. Int Forum Allergy Rhinol. 2019;9(4):388-395.
Kaulsay R, Nguyen DT, Kuhl HC. Real-life effectiveness of MP-AzeFlu in Irish patients with persistent allergic rhinitis, assessed by visual analogue scale and endoscopy. Immun Inflamm Dis. 2018;6(4):456-464.
Pohl W, Kaulsay R, Stjärne P. Real life effectiveness of MP-AzeFlu® in persistent allergic rhinitis, assessed by visual analogue scale and endoscopy: pooled data from Austria, Ireland and Sweden. Posters presented at SERIN 2017.
Stjarne P, Strand V, Theman K, Ehnhage A. Control of allergic rhinitis with MP-AzeFlu: a noninterventional study of a Swedish cohort. Rhinology. 2019;57:279–86.
Klimek L, Price D, Gálffy G, et al. Effect of Specific Immunoglobulin E Response and Comorbidities on Effectiveness of MP-AzeFlu in a Real-Life Study. Int Arch Allergy Immunol. 2020;181(10):754-764.
Price D, Klimek L, Gálffy G, et al. Allergic rhinitis and asthma symptoms in a real-life study of MP-AzeFlu to treat multimorbid allergic rhinitis and asthma. Clin Mol Allergy. 2020;18:15.
Van Weissenbruch R, Klimek L, Gálffy G, et al. MP-AzeFlu Improves the Quality-of-Life of Patients with Allergic Rhinitis. J Asthma Allergy. 2020;13:633-645.
Bousquet J, Meltzer EO, Couroux P, et al. Onset of Action of the Fixed Combination Intranasal Azelastine-Fluticasone Propionate in an Allergen Exposure Chamber. J Allergy Clin Immunol Pract. 2018;6(5):1726-1732.e6.
Canonica GW, Klimek L, Acaster S, et al. Burden of allergic rhinitis and impact of MP-AzeFlu from the patient perspective: pan European patient survey. Curr Med Res Opin. 2021; 37(7):1259-1272.
Dymista® Summary of Product Characteristic, 2022.
Bachert C, Cardell LO. The journey from unmet need in allergic rhinitis to rationale for, and clinical development of, a new treatment option, MP29-02. Clin. Pract. 2014; 11(4):413-424.
Prenner BM. A review of the clinical efficacy and safety of MP-AzeFlu, a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate, in clinical studies conducted during different allergy seasons in the US. J Asthma Allergy. 2016;9:135-143.
Berger WE, Shah S, Lieberman P, et al. Long-term, randomized safety study of MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system) in subjects with chronic rhinitis. J Allergy Clin Immunol Pract. 2014;2(2):179-185.
Derendorf H, Munzel U, Petzold U, et al. Bioavailability and disposition of azelastine and fluticasone propionate when delivered by MP29-02, a novel aqueous nasal spray. Br J Clin Pharmacol. 2012;74(1):125-133.
Maciej kozminski et al, Thixotropy of nasal medications-its role in clinical practice, Pneumonol Alergol Pol 2015; 83: 157–163.